复星医药(600196.SH): HLX18用于多种实体瘤治疗开展Ⅰ期临床试验获批准

智通财经
Yesterday

智通财经APP讯,复星医药(600196.SH)公告, 公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意 HLX18(即重组抗 PD-1 人源化单克隆抗体注射液)用于多种实体瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后于中国境内 1开展该药品的相关临床研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10